3 suspended. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Suspended 3 |
| Phase 1 | 2 | Suspended 2 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-08 | 2026-11-03 |
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Neratinib, Divalproex Sodium - Solid Tumor, Adult | Phase 1 / Phase 2 | Suspended | Virginia Commonwealth University | 80 | 2019-05-01 | 2026-10-21 |
| Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate - HIV Infections | Phase 2 | Suspended | Agouron Pharmaceuticals | 350 | 1999-08-01 | 2005-06-24 |
Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · HIV Infections (1) · Pancreatic Neoplasms (1) · Pathologic Complete Response (1)
Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Neoplasms (2) · Neoplasms by Site (2) · Blood-Borne Infections (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1)
Azacitidine (1) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Nelfinavir (1) · Paclitaxel (1) · Pemetrexed (1) · Valproic Acid (1) · capravirine (1) · durvalumab (1) · lamivudine, zidovudine drug combination (1) · neratinib (1)
Agouron Pharmaceuticals (1) · National Cancer Institute (NCI) (1) · Virginia Commonwealth University (1)
United States (3) · Canada (1) · Dominican Republic (1) · Puerto Rico (1)
Andrew Poklepovic, MD (1) · David S Schrump, M.D. (1)